pioglitazone has been researched along with Vascular Diseases in 7 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with previous stroke (n=486 in the pioglitazone group and n=498 in the placebo group), there was a trend of benefit with pioglitazone for the primary end point of all-cause death, nonfatal myocardial infarction, acute coronary syndrome, and cardiac intervention (including coronary artery bypass graft or percutaneous coronary intervention), stroke, major leg amputation, or bypass surgery or leg revascularization (hazard ratio[HR]=0." | 9.12 | Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). ( Betteridge, DJ; Bousser, MG; Dormandy, J; Kupfer, S; Pirags, V; Schernthaner, G; Wilcox, R, 2007) |
| "In patients with previous stroke (n=486 in the pioglitazone group and n=498 in the placebo group), there was a trend of benefit with pioglitazone for the primary end point of all-cause death, nonfatal myocardial infarction, acute coronary syndrome, and cardiac intervention (including coronary artery bypass graft or percutaneous coronary intervention), stroke, major leg amputation, or bypass surgery or leg revascularization (hazard ratio[HR]=0." | 5.12 | Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). ( Betteridge, DJ; Bousser, MG; Dormandy, J; Kupfer, S; Pirags, V; Schernthaner, G; Wilcox, R, 2007) |
| "Pioglitazone treatment increased direct costs by CHF 10,914 per patient over a lifetime horizon." | 2.74 | Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. ( Brändle, M; Erdmann, E; Erny-Albrecht, KM; Goodall, G; Valentine, WJ, 2009) |
| "Treatment with pioglitazone may offer a new effect on the whole vessel wall, promoting the stability of advanced atherosclerotic plaques." | 1.48 | Vascular dysfunction elicited by a cross talk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone. ( Cannizzo, B; Castro, C; Cejas, J; García, R; Quesada, I; Redondo, A, 2018) |
| "Pioglitazone can suppress the oxidative stress and damage and can stimulate antioxidant capacity in cardiac allografts after transplantation." | 1.37 | Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. ( Hasegawa, T; Okada, K; Okita, Y; Pinsky, DJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quesada, I | 1 |
| Cejas, J | 1 |
| García, R | 1 |
| Cannizzo, B | 1 |
| Redondo, A | 1 |
| Castro, C | 1 |
| Krentz, A | 1 |
| Brändle, M | 1 |
| Goodall, G | 1 |
| Erny-Albrecht, KM | 1 |
| Erdmann, E | 1 |
| Valentine, WJ | 1 |
| Kurabayashi, M | 1 |
| Hasegawa, T | 1 |
| Okada, K | 1 |
| Okita, Y | 1 |
| Pinsky, DJ | 1 |
| Pratley, RE | 1 |
| Wilcox, R | 1 |
| Bousser, MG | 1 |
| Betteridge, DJ | 1 |
| Schernthaner, G | 1 |
| Pirags, V | 1 |
| Kupfer, S | 1 |
| Dormandy, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pioglitazone and Vascular Diseases
| Article | Year |
|---|---|
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; | 2009 |
[Anti-vascular failure effects].
Topics: Animals; Humans; Ligands; Mice; Pioglitazone; PPAR gamma; Thiazolidinediones; Vascular Diseases | 2010 |
2 trials available for pioglitazone and Vascular Diseases
| Article | Year |
|---|---|
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; | 2009 |
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
Topics: Adult; Aged; Cardiovascular Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Co | 2007 |
3 other studies available for pioglitazone and Vascular Diseases
| Article | Year |
|---|---|
Vascular dysfunction elicited by a cross talk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone.
Topics: Adipose Tissue; Animals; Aorta; Apolipoproteins E; Blood Glucose; Blood Vessels; Fructose; Hypoglyce | 2018 |
Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation.
Topics: Animals; Graft Survival; Heart Transplantation; Hypoglycemic Agents; Lipid Peroxidation; Male; Mice; | 2011 |
The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazol | 2006 |